-
公开(公告)号：US20230250100A1
公开(公告)日：2023-08-10
申请号：US18134455
申请日：2023-04-13
发明人： Joseph Walter Strohbach , David Christopher Limburg , John Paul Mathias , Atli Thorarensen , Rajiah Aldrin Denny , Christoph Wolfgang Zapf , Daniel Elbaum , Lori Krim Gavrin , Ivan Viktorovich Efremov
IPC分类号： C07D487/04 , A61P11/12 , A61K31/519 , A61K45/06
CPC分类号： C07D487/04 , A61P11/12 , A61K31/519 , A61K45/06
摘要： The present invention relates to methods of using compounds of Formula I,
wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.-
公开(公告)号：US20180104424A1
公开(公告)日：2018-04-19
申请号：US15729526
申请日：2017-10-10
发明人： Henri Akouka , Daniel Becker , Renee Hyer , Craig Oakum
IPC分类号： A61M15/00 , A61M16/14 , A61K9/00 , A61P11/00 , A61P11/06 , A61K38/46 , A61K31/4418 , A61K31/167 , A61K31/40 , A61P11/12
CPC分类号： A61M15/0091 , A61K9/0075 , A61K31/167 , A61K31/40 , A61K31/4418 , A61K38/465 , A61M15/001 , A61M15/0021 , A61M15/0051 , A61M15/0085 , A61M15/0086 , A61M16/14 , A61M2016/0021 , A61M2016/0027 , A61M2016/0039 , A61M2202/064 , A61M2205/502 , A61M2205/583 , A61M2205/8206 , A61P11/00 , A61P11/06 , A61P11/12
摘要： A medicament delivery device comprises a dosing chamber configured to contain dry powder medicament, a transducer and a controller electrically coupled to the transducer. The medicament delivery device is capable of delivering a therapeutically effective dose of dry powder medicament in response to between 2-20 tidal inhalations, the dose preferably having a mass median aerodynamic diameter (MMAD) of about 6 microns or less and a fine particle fraction of at least 30%.
-
公开(公告)号：US11739094B2
公开(公告)日：2023-08-29
申请号：US17103559
申请日：2020-11-24
发明人： Clive McCarthy , Jonathan David Hargrave , Duncan Alexander Hay , Thomas Beauregard Schofield , Naomi Went
IPC分类号： C07D487/04 , A61P11/12 , A61K9/00 , A61K45/06
CPC分类号： C07D487/04 , A61K9/007 , A61P11/12 , A61K45/06
摘要： Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
-
公开(公告)号：US11697693B2
公开(公告)日：2023-07-11
申请号：US17385497
申请日：2021-07-26
IPC分类号： C08B37/00 , A61P11/12 , A61P31/04 , A01N65/03 , A61K31/734
CPC分类号： C08B37/0084 , A01N65/03 , A61K31/734 , A61P11/12 , A61P31/04
摘要： Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.
-
公开(公告)号：US20180333457A1
公开(公告)日：2018-11-22
申请号：US15981757
申请日：2018-05-16
申请人： Translate Bio, Inc.
发明人： Michael Heartlein , Frank DeRosa , Alan Kimura , Jonathan Abysalh , Anusha Dias , Shrirang Karve , Zarna Patel
CPC分类号： A61K38/1709 , A61K9/0078 , A61K9/127 , A61K48/0075 , A61P11/12
摘要： The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.
-
公开(公告)号：US20230142208A1
公开(公告)日：2023-05-11
申请号：US17906512
申请日：2021-03-23
发明人： Al Czap
IPC分类号： A61K47/69 , A61K9/48 , A61K38/47 , A61P11/12 , A61P15/10 , A61K31/519 , A61K36/534 , A61K36/61 , A61K31/015
CPC分类号： A61K47/6951 , A61K9/4866 , A61K9/4858 , A61K38/47 , C12Y302/01001 , A61P11/12 , A61P15/10 , A61K31/519 , A61K36/534 , A61K36/61 , A61K31/015
摘要： The invention provides oral terpene cyclodextrin inclusion complex delivery vehicles, including formulations in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of time release formulations, for example for treatment of airway mucus dysfunction. Formulations are also provided with erectogenic efficacy.
-
公开(公告)号：US11642380B2
公开(公告)日：2023-05-09
申请号：US17361684
申请日：2021-06-29
申请人： WELL STONE CO.
发明人： Yoichi Ishii , Takeshi Okamoto , Sayaka Makino
摘要： Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.
-
公开(公告)号：US20180264032A1
公开(公告)日：2018-09-20
申请号：US15534011
申请日：2016-02-05
发明人： Syed Jafri , Wolfgang SCHMEHL
IPC分类号： A61K33/00 , A61K45/06 , A61K9/00 , A61P11/06 , A61P11/12 , A61P31/12 , A61P31/04 , A61M16/12
CPC分类号： A61K33/00 , A61K9/0075 , A61K9/0078 , A61K33/08 , A61K45/06 , A61K2300/00 , A61M16/12 , A61M16/125 , A61M2202/0208 , A61M2202/025 , A61M2202/0275 , A61P11/06 , A61P11/12 , A61P31/04 , A61P31/12
摘要： An apparatus for the treatment of infections associated with respiratory disorders in a mammal with a mixture for use as an inhalable medicament. The apparatus includes a patient interface, at least one source of helium for providing gaseous helium, at least one source of oxygen for providing gaseous oxygen, an application device for providing a mixture to the patient interface, at least one source of nitric oxide for providing gaseous nitric oxide, a gas injector for injecting the nitric oxide into the mixture, an injector for injecting a means for inhibiting growth of pulmonary pathogens, a controller programmed for controlling the gas injector, the application device and the injector.
-
公开(公告)号：US20180125838A1
公开(公告)日：2018-05-10
申请号：US15793767
申请日：2017-10-25
发明人： Vinita Uttamsingh
CPC分类号： A61K31/47 , A61K9/0053 , A61K9/14 , A61K9/20 , A61K9/2054 , A61P11/12
摘要： Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. The method comprises administering to the subject Compound (I): or pharmaceutically acceptable salts thereof, together with food. Also disclosed are products comprising Compound (I) and the use of such products.
-
公开(公告)号：US20240299489A9
公开(公告)日：2024-09-12
申请号：US17449679
申请日：2021-10-01
申请人： Translate Bio, Inc.
发明人： Michael Heartlein , Frank DeRosa , Alan Kimura , Jonathan Abysalh , Anusha Dias , Shrirang Karve , Zarna Patel
CPC分类号： A61K38/1709 , A61K9/0078 , A61K9/127 , A61K48/0075 , A61P11/12 , C12N15/88
摘要： The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.015 秒)
